REGISTERED NUMBER: 05278706 (England and Wales)

Report of the Director and

Unaudited Financial Statements for the Year Ended 31 December 2024

for

Bioplax Limited

Page

Company Information

1

Report of the Director

2

Chartered Accountants' Report

3

Income Statement

4

Statement of Financial Position

5

Notes to the Financial Statements

6

DIRECTOR:

A Artioli

REGISTERED OFFICE:

Endeavour House

78 Stafford Road

Wallington

Surrey

SM6 9AY

REGISTERED NUMBER:

05278706 (England and Wales)

ACCOUNTANTS:

PB Partners LLP

Endeavour House

78 Stafford Road

Wallington

Surrey

SM6 9AY

The director presents his report with the financial statements of the company for the year ended 31 December 2024.

PRINCIPAL ACTIVITY

The principal activity of the company in the year under review was that of holding patents and trademarks and to trade in the pharmaceutical industry.

DIRECTOR

A Artioli held office during the whole of the period from 1 January 2024 to the date of this report.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

A Artioli - Director

24 September 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Bioplax Limited for the year ended 31 December 2024 which comprise the Income Statement, Statement of Financial Position and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Bioplax Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Bioplax Limited and state those matters that we have agreed to state to the director of Bioplax Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Bioplax Limited and its director for our work or for this report.

It is your duty to ensure that Bioplax Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Bioplax Limited. You consider that Bioplax Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Bioplax Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

PB Partners LLP

Endeavour House

78 Stafford Road

Wallington

Surrey

SM6 9AY

24 September 2025

TURNOVER

75,000

-

Cost of sales

139

134

GROSS PROFIT/(LOSS)

74,861

(134

)

Administrative expenses

104,973

124,174

OPERATING LOSS and

LOSS BEFORE TAXATION

(30,112

)

(124,308

)

Tax on loss

-

-

LOSS FOR THE FINANCIAL YEAR

(30,112

)

(124,308

)

CURRENT ASSETS

Debtors

5

2,589

2,240

Cash at bank

293,551

301,909

296,140

304,149

CREDITORS

Amounts falling due within one year

6

27,914

5,811

NET CURRENT ASSETS

268,226

298,338

TOTAL ASSETS LESS CURRENT LIABILITIES

268,226

298,338

CAPITAL AND RESERVES

Called up share capital

100,003

100,003

Retained earnings

168,223

198,335

268,226

298,338

268,226

298,338

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the director and authorised for issue on 24 September 2025 and were signed by:

A Artioli - Director

1.	STATUTORY INFORMATION

Bioplax Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Euro (€).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents & trademarks have been fully amortised.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4.	INTANGIBLE FIXED ASSETS

Patents &

trademarks

€

COST

At 1 January 2024

and 31 December 2024

165,916

AMORTISATION

At 1 January 2024

and 31 December 2024

165,916

NET BOOK VALUE

At 31 December 2024

-

At 31 December 2023

-

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

€

€

Social security and other taxes

1,760

1,411

Prepayments

829

829

2,589

2,240

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

€

€

Trade creditors

27,914

5,811

7.	CONTROLLING PARTY

The controlling party is Esperia Servizi Fiduciari SpA, whose Registered Office is Via Dante 16, 20121 Milan MI, Italy